The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia

  17 April 2024

Drug Resistant Tuberculosis (DR-TB) is a significant public health and economic problem globally, affecting individuals in economically productive years and hindering workforce growth. A study in Zambia found that DR-TB prevalence in the Central Province was 1.4%, with 63.9% of affected adults aged 26-45 years. The majority of patients were from Kabwe District, with 89.6% having RR-TB and 6.2% having MDR-TB. Outcomes showed that 16.9% of patients were declared cured, 45.9% completed treatment, 6% lost to follow-up, and 21.3% died. Risk factors for mortality included age and male gender. The study recommends measures to improve surveillance, early detection, treatment initiation, and patient follow-up.

Further reading: Springer Link
Author(s): Evaristo Chanda
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed